康普茶是一种发酵的非酒精茶饮料,通过细菌和酵母的共生培养产生。体外研究表明抗菌,抗氧化剂,抗增殖,和红茶菌的抗癌特性。然而,目前还没有系统评价康普茶在体内的作用.因此,我们的目的是评估迄今存在的关于红茶菌消费对肥胖相关合并症以及肠道微生物群的影响的证据.根据PRISMA进行搜索,并在PROSPERO(注册号:CRD42020158917)中注册了协议。MEDLINE/PubMed,WebofScience,LILACS,SciELO,Scopus,和ScienceDirect数据库在搜索中考虑以下术语:\“红茶菌\”或\“红茶菌\”或\“红茶菌\”或\”茶,红茶茶或茶,康普茶“不”评论。“15项研究纳入本综述。结果表明,红茶菌的消费减弱氧化应激和炎症,改善肝脏排毒过程,并减少肠道生态失调。有证据表明,红茶菌的消费有利于控制和治疗肥胖和相关的合并症,以及体内肠道微生物群的调节。
Kombucha is a fermented nonalcoholic tea-based beverage produced through a symbiotic culture of bacteria and yeasts. In vitro studies have demonstrated antimicrobial, antioxidant, antiproliferative, and anti-carcinogenic properties of kombucha. However, no systematic reviews have evaluated the effects of kombucha in vivo. Thus, we aimed to evaluate the evidence that exists so far about kombucha consumption on comorbidities associated with obesity as well as on the gut microbiota. The search was conducted in accordance with PRISMA and the protocol was registered in PROSPERO (registration number: CRD42020158917). The MEDLINE/PubMed, Web of Science, LILACS, SciELO, Scopus, and Science Direct databases were used in the search considering the following terms: \"kombucha\" OR \"kombucha tea\" OR \"kombucha teas\" OR \"tea, kombucha\" OR \"teas, kombucha\" NOT \"
review.\" Fifteen studies were included in this
review. The results suggest that kombucha consumption attenuates oxidative stress and inflammation, improves the liver detoxification process, and reduces intestinal dysbiosis. There is evidence that kombucha consumption is beneficial for the control and treatment of obesity and associated comorbidities, as well as for the modulation of the gut microbiota in vivo.